Five Medtech Trends Reshaping the Industry in 2026

2026 Medtech Trends: Market & Industry Insights

Five forces redefining medical technology competition and care delivery

The medtech industry is heading into 2026 amid structural shifts that are redefining how medical devices are priced, adopted, and integrated into clinical practice. From evolving procurement policies in China to the growing role of ambulatory surgical centers, the competitive landscape is being reshaped by forces that extend far beyond innovation alone. Understanding these trends is essential for manufacturers, investors, and healthcare leaders seeking to align strategy with the realities of a rapidly changing market.

Based on Clarivate’s comprehensive analysis, five key trends stand out as particularly consequential for the year ahead.

---

1. Mainland China’s Volume-Based Procurement Expansion is Redefining Global Market Economics

Mainland China’s national volume-based procurement (VBP) program has evolved from an access-expanding policy into a powerful market-structuring mechanism. The latest round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech firms, VBP is no longer a localized issue; it now influences pricing expectations and competitive positioning in markets worldwide.

Why it matters: The policy is accelerating domestic innovation while forcing global companies to rethink portfolio strategy and market participation. As VBP expands into new device categories, multinationals must navigate a landscape where price and volume dynamics are increasingly dictated by government benchmarks. The spillover effect into other Asia-Pacific and emerging markets could further complicate global pricing strategies.

2. Outpatient and ASC Settings Are Becoming Central to Procedure Strategy

The Center for Medicare & Medicaid Services (CMS) 2026 Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule expands the ASC Covered Procedure List and accelerates the phasing out of the inpatient-only list. This opens the door for higher-acuity procedures, including cardiac ablation, to be performed in lower-cost settings when clinically appropriate. The shift aligns with long-running trends in orthopedics, general surgery, and other specialties.

Why it matters: As more procedures become ASC-eligible, medtech companies must adapt their commercial models, economic value propositions, and product designs to meet the needs of diverse sites of service. The emergence of office-based labs and outpatient hospitals further complicates the traditional sales strategy. Manufacturers must now demonstrate value across the full continuum of care, from patient outcomes to cost efficiency.

3. Global Trade and Supply Chain Pressures Are Reshaping Manufacturing Strategy

Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging long-held assumptions about where and how medical devices are produced. In response, companies are diversifying sourcing, re-evaluating business strategies, and pursuing flexible multi-region manufacturing footprints. Larger players are leveraging scale, integration, and technology investment to buffer against volatility, which could reshape competitive dynamics across categories.

Why it matters: Cost structures, supplier concentration, and manufacturing geography are becoming as important as product performance in determining competitive advantage. Companies that fail to build resilience may face margin pressure and supply disruptions. The trend also underscores the growing convergence of medtech and industrial policy, with governments increasingly viewing domestic manufacturing capacity as a strategic asset.

4. GLP-1 Therapies Are Shifting Patient Behavior and Reshaping Care Pathways

The widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded the addressable population and changed referral patterns. Downstream effects are emerging across diabetes care, sleep apnea, cardiovascular monitoring, and even orthopedic procedures, as weight loss affects demand for joint replacement.

Why it matters: The GLP-1 effect reflects a broader shift in metabolic disease management, with ripple effects across multiple device markets. Medtech companies must assess their exposure to diabetes, cardiovascular, and obesity-related product lines, and consider how combination therapy or sequential treatment pathways will shape future procedure volumes. The long-term impact on surgical weight loss volumes remains uncertain, but early data suggest a measurable decline in certain bariatric procedures.

5. Enabling Technologies Are Driving the Move Toward Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts to procedures—they are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Companies are investing heavily in platform architectures that anchor entire service lines, strengthen customer relationships, and unlock data-driven value propositions. Open-platform systems are also expanding flexibility and creating new competitive dynamics.

Why it matters: Platform-based competition is redefining how companies deliver value and engage customers. The integration of hardware with software and data analytics creates high switching costs and deepens moats. At the same time, interoperability and open standards are prompting new entrants and partnerships that could disrupt incumbents. The ability to manage and analyze procedural data is increasingly a point of differentiation.

---

Industry Impact

These trends have profound implications for the biotechnology and medical technology industry. Companies must recalibrate their market access strategies in response to China’s VBP program, adapt to the migration of procedures to outpatient settings, and invest in supply chain resilience. The rise of GLP-1 therapies demands closer coordination between pharmaceutical and device strategies, while the shift toward platform-based competition requires new capabilities in software, data analytics, and ecosystem development.

Investment priorities are shifting accordingly. Investors are increasingly valuing companies with diversified manufacturing footprints, robust digital platforms, and the ability to demonstrate value-based outcomes. Partnerships that combine device expertise with data science and artificial intelligence will likely outperform those that rely solely on hardware innovation.

Clinical & Regulatory Perspective

From a clinical perspective, the trends reflect a healthcare system in transition. The expansion of ASC procedures has the potential to improve patient convenience and reduce costs, but requires rigorous patient selection and quality monitoring. The GLP-1 revolution is reshaping clinical pathways, yet long-term adherence, discontinuation, and treatment sequencing remain important questions.

Regulatory frameworks are also adapting. The CMS policy changes are a key driver of site-of-care shifts, and VBP is setting new precedents for how governments control healthcare costs. Medtech companies must engage with regulatory bodies not just on safety and efficacy, but also on reimbursement, coverage, and health economic evidence. Future regulatory decisions will increasingly be informed by real-world data and digital biomarkers.

Future Outlook

Looking ahead to the next 5–15 years, these trends will continue to evolve. China’s VBP is likely to expand to more categories and its influence may be felt in other emerging markets. Outpatient care will continue to grow, possibly incorporating more complex procedures as technology advances. Supply chain networks will become more regionalized and digitized, perhaps with the help of additive manufacturing and predictive analytics.

The GLP-1 class is expected to expand beyond weight management into broader metabolic and cardiovascular indications, with unknown implications for device demand. Platform-based competition will intensify, with AI-driven decision support and closed-loop systems becoming the norm. The boundaries between medical devices, pharmaceuticals, and digital health will continue to blur, creating new opportunities and challenges for all stakeholders.

Key Takeaways

• China’s VBP has evolved into a global market-shaping force, requiring multinational medtech companies to rethink pricing and portfolio strategy.
• CMS payment rules are accelerating the migration of procedures to outpatient and ASC settings, changing the economics of medical device commercialization.
• Supply chain resilience is now a strategic imperative; manufacturing footprint and sourcing diversification are key determinants of competitiveness.
• GLP-1 therapies are disrupting traditional medtech categories and creating cross-sector ripple effects that demand integrated commercial planning.
• Platform-based competition is redefining value creation, with integrated ecosystems of robotics, imaging, and digital workflows becoming the basis of market leadership.

Sources

• Clarivate. “Medtech Trends to Watch in 2026.” April 2026. Link.